Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961163 | 0.83 | PRKCA (0.33) | — | |
| SCHEMBL8593083 | 0.73 | ALDH1A1 (0.34) | LMNACYP2C9 | |
| SCHEMBL3389445 | 0.71 | ALDH1A1 (0.36) | LMNACYP2C9 | |
| SCHEMBL14037116 | 0.68 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL30295407 | 0.68 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL10442413 | 0.67 | DPP4 (0.34) | LMNACYP2C9 | |
| SCHEMBL8459306 | 0.67 | CYP2C9 (0.32) | LMNACYP2C9 | |
| SCHEMBL7563469 | 0.66 | LMNA (0.33) | LMNACYP2C9 | |
| SCHEMBL26477096 | 0.65 | PAOX (0.34) | — | |
| SCHEMBL12836369 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0898562-B1 | HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION | UPJOHN CO (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-0898562-A1 | HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5712300-A | ENZYME INHIBITOR | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1997032846-A1 | HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-12 | — | — | WO | disclosed |